Table S1. Description of study population at baseline Anal Health Study (AHS) visit, by adequate/ inadequate baseline ACyt.

	N (%)		
	Adequate (N = 1276)	**Inadequate (N = 235)**	**P-value**
HIV Status			0.077
HIV-Uninfected	653 (51%)	135 (57%)	
HIV-Infected	623 (49%)	100 (43%)	
Current ART use	565 (91%)	94 (94%)	0.279
Race			0.188
White	930 (73%)	156 (66%)	
Black	218 (17%)	53 (23%)	
Hispanic	105 (8%)	22 (9%)	
Other	23 (2%)	4 (2%)	
Center			0.007
Baltimore	292 (23%)	67 (29%)	
Chicago	266 (21%)	36 (15%)	
Pittsburgh	324 (25%)	44 (19%)	
Los Angeles	394 (31%)	88 (37%)	
Smoking Status			0.334
Never	355 (29%)	55 (25%)	
Former	628 (51%)	114 (52%)	
Current	246 (20%)	52 (24%)	
# of anal receptive partners in 6 months prior to first ACty			0.147
0	767 (63%)	150 (68%)	
1	209 (17%)	38 (17%)	
≥ 2	239 (20%)	31 (14%)	
Ever had HRA?	81 (6%)	7 (3%)	<0.001
Ever diagnosed with invasive anal cancer?	10 (1%)	5 (2%)	0.069
HIV viral lead, copies/mL			0.266
Undetectable (≤40)	479 (77%)	82 (82%)	
Detectable (>40)	143 (23%)	18 (18%)	
	Median (IQR)		
Age, years	55 (49,61)	55 (49,61)	0.944
Current CD4 T cell count, cells/mm^3	582 (420,757)	599 (461,808)	<0.001